The largest database of trusted experimental protocols

Qiamp dna blood mini kit

Manufactured by Qiagen
Sourced in Germany, United States, United Kingdom, Spain, France, Italy, Netherlands

The QIAamp DNA Blood Mini Kit is a product designed for the purification of genomic DNA from whole blood samples. It utilizes a silica-based membrane technology to efficiently capture and purify DNA. The kit provides a rapid and reliable method for extracting high-quality DNA, which can be used for various downstream applications such as PCR, sequencing, and molecular analysis.

Automatically generated - may contain errors

337 protocols using qiamp dna blood mini kit

1

Extraction and Detection of Coxiella burnetii DNA

Check if the same lab product or an alternative is used in the 5 most similar protocols
Before DNA extraction, dust swabs were treated with 300 µL of TE buffer (Tris base 10 mM, EDTA 1 mM, pH 8) before being mixed with ATL and proteinase K for 1 h at 56 °C, and then, DNA extraction continued using the QIAmp DNA blood mini kit (Qiagen, Hilden, Germany). For aerosol samples, gelatine filters used in the air sampler device were treated with 2 mL of ATL buffer until gelatine was dissolved. This solution was mixed with 500 µL of buffer ATL and vortexed, centrifuged and heated at 56 °C. Then, two aliquots of 1 mL each were taken, and 50 µL of proteinase K (8 mg/mL) were added to each one, and the mixture was incubated for 1 h at 56 °C. The extraction process continued using QIAmp DNA blood mini kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. Negative extraction controls were included every 10 samples to rule out DNA contamination. The presence of C. burnetii DNA was investigated by a real-time PCR amplification targeting the transposon-like repetitive region IS1111 of the C. burnetii genome [20 (link)]. A commercial internal amplification control (IAC) (TaqMan®® exogenous internal positive control, Thermo Fisher Scientific) was included in the assay to monitor for PCR inhibitors.
+ Open protocol
+ Expand
2

Genetic Analysis of Retinal Degeneration

Check if the same lab product or an alternative is used in the 5 most similar protocols
Four siblings, including two patients and two asymptomatic individuals, and their unaffected parents, were recruited from Ningxia People’s Hospital. Written informed consents were obtained from all participants or their legal guardians. Our study, adhered to tenets of the Declaration of Helsinki, was approved and prospectively reviewed by the Ethics Committee on Human Research at Ningxia People’s Hospital. Each participant received routine ophthalmic examinations, while the two patients and the unaffected mother underwent complete ophthalmic examinations, including assessments of BCVAs, slit-lamp examination, funduscopy, color vision test, VF tests (Humphrey perimetry), VEP, ERG and OCT examinations. FAF imaging and FFA was selectively conducted on the proband, patient YZ-II:4. Additionally, 150 unrelated healthy controls free of retinal or other major ocular diseases were also included. Peripheral venous blood samples (5 mL) were collected from all included participants for genomic DNA isolation with a QIAmp DNA Mini Blood Kit (Qiagen, Hilden, Germany).
+ Open protocol
+ Expand
3

Whole Exome Sequencing for Genomic Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral venous blood sample (5 ml) was collected from the participant for genomic DNA extraction using a QIAmp DNA Mini Blood Kit (Qiagen, Hilden, Germany). Whole exome sequencing was performed on the probands. The exome was captured using the Agilent SureSelect Exon Capture Kit according to manufacturer’s instructions. Sequencing was performed using a high-throughput sequencer (Illumina, HiSeq XTen). Raw sequencing data were processed using Illumina basecalling Software 1.7 analysis software following which it was compared to the NCBI human genomic DNA reference sequence (NCBI build 37.1). To obtain all variants occurring in the DNA sequences of the samples, single-nucleotide variants (SNV) and insertion and deletion variants (Indel) were analyzed using SOAP software (http://soap.genomics.org.cn), and BWA software (http://bio-bwa.sourceforge.net), respectively. The BWA software was used to compare with the hg19 human genome reference sequence provided by UCSC, and the SNV and InDel variants were found out through GATK’s HaplotypeCaller, and then through professional database. Sanger validation was used to exclude false positives for potential pathogenic variants.
+ Open protocol
+ Expand
4

Monitoring Liquid Biopsy for Metastatic CRC

Check if the same lab product or an alternative is used in the 5 most similar protocols
We retrospectively assessed archival tissue and plasma samples at baseline for mutational status, with repeat plasma samples occurring every 4 cycles prior to each restaging CT scan (2 to 6 hours after taking the daily dose of dasatinib). Investigators were blinded to the results of the clinical grade assay during the experiment. Plasma samples for cfDNA analysis were stored at −80°C and transferred between institutions on dry ice. The plasma isolation protocol we adapted from Chiu et al (35 (link)) as well as handling and storage conditions were previously described (36 ). Briefly, plasma was first centrifuged at 1600g at 4C° for 10 minutes and supernatant was centrifuged at 16,000g at 4°C for 10 minutes. Supernatant was immediately used for DNA extraction and stored at −20°C. Total cfDNA was extracted from 1mL of isolated plasma using the QIAmp DNA mini blood kit (Qiagen, CA) in accordance with the pre-analytical guidelines we previously described (36 ) in an elution volume of 130μL. DNA extracts were kept at −20°C until use or used immediately. In total, we analyzed 81 serial plasma samples from 46 mCRC patients (Supplemental Figure S1).
+ Open protocol
+ Expand
5

Circulating DNA Extraction from Biofluids

Check if the same lab product or an alternative is used in the 5 most similar protocols
CirDNA from plasma, serum or cell medium was extracted using the QIAmp DNA Mini Blood kit (Qiagen), used according to the “Blood and body fluid protocol,” using 80 µl of elution volume. DNA extracts were kept at − 20 °C until used.
+ Open protocol
+ Expand
6

Plasma cfDNA Extraction Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
All blood samples were collected in 4-milliliter EDTA tubes. The blood was then centrifuged at 1200g at 4°C for 10 minutes. The supernatants were isolated in sterile 1.55 mL Eppendorf tubes and centrifuged at 16,000g at 4°C for 10 minutes. Afterward, the plasma was either immediately used for DNA extraction or stored at –20°C. CfDNA was extracted from 1 mL of plasma using the QIAmp DNA Mini Blood kit (Qiagen) according to the “Blood and body fluid protocol.” DNA extracts were kept at –20°C until used. The preanalytical conditions we followed are described (45 (link)).
+ Open protocol
+ Expand
7

Evaluating Circulating DNA Stability

Check if the same lab product or an alternative is used in the 5 most similar protocols
The 20 µl of chromatin equivalent to 200 ng of genomic DNA was added to 5 aliquots of 500 µL of blood EDTA, plasma EDTA, or serum. These samples were incubated at 37 °C for 0 min, 30 min, 2 h, 8 h, and 24 h. After incubation, the plasma was isolated from blood EDTA as described above. Then, cfDNA was extracted from 0.5 ml of plasma or serum using the QIAmp DNA Mini Blood kit (Qiagen, CA), according to the “Blood and body fluid protocol” and our own detailed protocol [38 (link)]. CfDNA samples were kept at 20 °C until use. Due to EDTA-associated calcium chelation inhibitory effect on nucleases, comparison of plasma vs serum incubation may help in estimating nuclease role in degrading gHMW DNA.
+ Open protocol
+ Expand
8

Whole Exome Sequencing for Genetic Diagnosis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Samples of peripheral venous blood (5 ml) were collected from patient and his parents for genomic DNA extraction using a QIAmp DNA Mini Blood Kit (Qiagen, Hilden, Germany). To reveal the disease causing mutation in this family, whole exome sequencing approach was performed on this family. Briefly, the libraries for whole exome sequence were established from the DNA samples using an exon capture kit (SureSelect ver. 6 + UTR, Agilent Technologies), according to the manufacturer’s instructions. The exons were sequenced as 100-basepairs paired-end reads by an Illumina HiSeq2500 (Illumina). The original sequencing data were processed by Illumina Basecalling Software 1.7 and compared with NCBI HUMAN genome DNA reference sequence (NCBI Build 37.1). Single nucleotide variation (SNV) information is analyzed using SOAP software (http://soap.Genomics.org.cn). The information related to Inserts and deletions (Indel) is analysed using BWA software (http://bio-bwa.sourceforge.net/) to obtain all the mutations occurring in the DNA sequences of the sample. The common variants (MAF > 1%) that appear in the database (DB135) are filtered out, and then those that have no effect on the structure and function of the protein are filtered out. Candidate pathogenic gene variants were obtained by filtration.
+ Open protocol
+ Expand
9

Genetic Analysis of Familial Maculopathy

Check if the same lab product or an alternative is used in the 5 most similar protocols
Our study conformed to the Declaration of Helsinki and was prospectively reviewed and approved by the ethics committee of Ningxia Eye Hospital. Written informed consent was obtained from all participants before their enrollment. Eighteen patients and 18 unaffected family members from family DC were included in the study (Figure 1). Medical records from each participant were reviewed. Routine ophthalmic examination was conducted for all participants, and all patients received comprehensive ophthalmic examinations, including best-corrected visual acuity, slit-lamp examination, visual field test, funduscopic evaluations, and electroretinograms. Fundus autofluorescence, fundus fluorescein angiography, optical coherence tomography, and electroretinography were performed when possible. Another 423 unrelated Chinese controls free of maculopathy and other major ocular diseases were also recruited. Samples of peripheral venous blood (5 ml) were collected from each participant for genomic DNA extraction using a QIAmp DNA Mini Blood Kit (Qiagen, Hilden, Germany).
+ Open protocol
+ Expand
10

Kinetics of NET Degradation by Serum

Check if the same lab product or an alternative is used in the 5 most similar protocols
As part of our study, we also investigated the kinetics of in vitro degradation by serum nucleases of the NET produced in the previous part of the study where NET induction was studied. This allows a direct comparison of the levels of NET formation vs production. To do so, the previously obtained supernatants of PMA-stimulated (5 h) neutrophils from a male individual were incubated with a fresh female serum for various time periods. We also used the X/Y differentiation to distinguish NET-derived male DNA from female cirDNA derived from serum. The qPCR analysis was performed targeting the SRY gene on the Y chromosome, and sWGS results took into consideration only reads aligning on the Y chromosome.
The 200 µl of supernatant of the PMA-stimulated neutrophils (5 h) equivalent to 50 ng of genomic DNA was added to aliquots of 500 µL of plasma or serum. These samples were incubated at 37 °C for 5 min, 10 min, 20 min, 30 min, 2 h, 8 h, and 24 h for NET degradation in serum, with 24 h incubation in plasma used as a control. After incubation, cfDNA was extracted from 0.5 ml of plasma/serum using the QIAmp DNA Mini Blood kit (Qiagen, CA), performed according to the “Blood and body fluid protocol” and our own detailed protocol [38 (link)]. CfDNA samples were kept at − 20 °C until use.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!